Merck’s 4,000% Markup of Taxpayer-Funded COVID Drug Is ‘Extortion,’ Critics Say

Pharma giant Merck is facing accusations of price gouging after it charged the U.S. more than $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce.